“Additionally, in all likelihood the completion
Post# of 147911
I believe NP’s hope is that the completion of the phase 2 mild to moderate trial coincides with the interim review of the phase 2/3 severe trial. That way, he can submit both data to the FDA and request approval. Throw in data from 50+ EIND patients as well (maybe 75+ by then).
Will that result in approval? Who knows. The FDA always wants more patients but maybe with very good results we can see a phase 4.